Clinical Trial Update: Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose frontline fludarabine, cyclophosphamide, and rituximab in chronic lymphocytic leukemia; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2016-08-23